高危或极高危前列腺癌根治术后活检分级组4降级情况
该研究汇总3家三级转诊中心2005至2015年间1776例接受根治性前列腺切除术的高危或极高危前列腺癌患者,分析其中726例活检分级组4患者的术后降级率。结果显示45%降级至分级组3或以下,高危患者降级率49%显著高于极高危29%(p<0.0001),多因素分析显示阳性活检针数较少与降级显著相关(p<0.01)。
要点
- 活检分级组4的高危/极高危患者中45%在根治术后降级至分级组3或以下。
- 高危患者任何降级率49%显著高于极高危患者29%(p<0.0001)。
- 阳性活检针数较少是多因素分析中与降级显著相关的因素(p<0.01)。
核心结论
- 在该高危/极高危前列腺癌队列中,活检分级组4在根治术后降级的发生率低于其他已发表报告。
- 极高危患者任何降级显著少于高危患者,降级至分级组2或以下在高危和极高危患者中均占少数。
研究设计与样本
- 回顾性汇总队列研究,纳入3家三级转诊中心2005至2015年间1776例接受根治性前列腺切除术的NCCN高危或极高危前列腺癌患者。
- 共识别893例活检分级组4患者,其中726例可用于分析。
- 采用多因素逻辑回归模型确定与根治术后降级至分级组3或以下相关的因素。
主要发现
- 333例(45%)在根治术后降级至分级组3或以下。
- 198例(27%)活检与根治术后病理分级组4一致,195例(27%)在根治术后升级至分级组5。
- 高危患者中活检分级组4的任何降级率为49%,极高危患者为29%(p<0.0001)。
- 降级至分级组2或以下在高危患者中占16%(98/604),在极高危患者中占7%(8/122)(p<0.01)。
- 降级病例的前列腺特异性抗原更低、阳性活检针数更少、临床分期更低(p<0.01);多因素分析中阳性活检针数较少与降级显著相关(p<0.01)。
临床怎么用
- 对于活检分级组4的高危/极高危前列腺癌患者,应知晓术后病理降级并非少见,尤其在高危且阳性针数较少的患者中。
- 极高危患者降级概率显著低于高危患者,咨询时应区别对待。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We examined rates of Grade Group 4 downgrading at radical prostatectomy among men diagnosed with high and very high risk prostate cancer at biopsy. MATERIALS AND METHODS: A pooled cohort of 1,776 patients from 3 tertiary referral centers who underwent radical prostatectomy for National Comprehensive Cancer Network® high risk (prostate specific antigen greater than 20 ng/ml, or Grade Group 4-5, or clinical stage T3 or greater) or very high risk (primary Gleason pattern 5, or more than 4 biopsy cores with Grade Group 4-5, or 2 or more high risk features) disease from 2005 to 2015 were reviewed. Overall 893 patients with Grade Group 4 disease at biopsy were identified and 726 patients were available for analysis. Multivariable logistic regression models were fit to determine factors associated with downgrading to Grade Group 3 or less at radical prostatectomy. RESULTS: Overall 333 (45%) cases were downgraded to Grade Group 3 or less at radical prostatectomy. Of these cases 198 (27%) had concordant Grade Group 4 biopsy and radical prostatectomy pathology and 195 (27%) were upgraded at radical prostatectomy to Grade Group 5. Of high risk cases with biopsy Grade Group 4 disease 49% had any downgrading vs 29% of very high risk cases (p <0.0001). Downgrading to Grade Group 2 or less occurred in 16% (98 of 604) of high risk and 7% (8 of 122) of very high risk cases (p <0.01). Downgraded cases had a lower prostate specific antigen, fewer positive biopsy cores and lower clinical stage (p <0.01). On multivariable analysis fewer positive biopsy cores were significantly associated with downgrading at radical prostatectomy (p <0.01). CONCLUSIONS: In this cohort of patients with high risk/very high risk prostate cancer, downgrading from biopsy Grade Group 4 at radical prostatectomy occurred less frequently than in other published reports. Any downgrading was significantly less common in very high risk compared to high risk patients, and downgrading to Grade Group 2 or less occurred in a minority of cases in high risk and very high risk patients.
引用
- Ranasinghe W, Reichard CA, Nyame YA, et al. Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer. J Urol. 2020. PMID: 32259468. doi:10.1097/JU.0000000000001074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。